Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease

Marie C Hogan, Augustine Lee, Lawrence A. Solberg, Stephan D. Thom

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Fludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases.

Original languageEnglish (US)
Pages (from-to)51-54
Number of pages4
JournalAmerican Journal of Hematology
Volume70
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Progressive Multifocal Leukoencephalopathy
JC Virus
Follicular Lymphoma
Therapeutics
Immunosuppressive Agents
Central Nervous System
Polymerase Chain Reaction
fludarabine
Infection
Neoplasms

Keywords

  • Chronic lymphocytic leukemia
  • Fludarabine
  • JC virus
  • Lymphoproliferative diseases
  • Progressive multifocal leukoencephalopathy

ASJC Scopus subject areas

  • Hematology

Cite this

Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. / Hogan, Marie C; Lee, Augustine; Solberg, Lawrence A.; Thom, Stephan D.

In: American Journal of Hematology, Vol. 70, No. 1, 2002, p. 51-54.

Research output: Contribution to journalArticle

Hogan, Marie C ; Lee, Augustine ; Solberg, Lawrence A. ; Thom, Stephan D. / Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. In: American Journal of Hematology. 2002 ; Vol. 70, No. 1. pp. 51-54.
@article{39130ccf418b45ef9c2794ac4b760ab5,
title = "Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease",
abstract = "Fludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases.",
keywords = "Chronic lymphocytic leukemia, Fludarabine, JC virus, Lymphoproliferative diseases, Progressive multifocal leukoencephalopathy",
author = "Hogan, {Marie C} and Augustine Lee and Solberg, {Lawrence A.} and Thom, {Stephan D.}",
year = "2002",
doi = "10.1002/ajh.10085",
language = "English (US)",
volume = "70",
pages = "51--54",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease

AU - Hogan, Marie C

AU - Lee, Augustine

AU - Solberg, Lawrence A.

AU - Thom, Stephan D.

PY - 2002

Y1 - 2002

N2 - Fludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases.

AB - Fludarabine is becoming the initial therapy for low-grade lymphoproliferative malignancies, such as CLL and follicular lymphoma. Fludarabine is highly immunosuppressive in addition to being myelosuppressive and has been associated with neurotoxicity. Progressive multifocal leukoencephalopathy (PML) is an infection with JC virus of the white matter of the central nervous system seen mostly in immunosuppressed patients. We describe two patients treated with fludarabine who developed PML. Immunolabeling was positive for JCV in both patients, but PCR was repeatedly negative in one of them. We suggest that fludarabine may increase the risk of PML in patients with lymphoproliferative diseases.

KW - Chronic lymphocytic leukemia

KW - Fludarabine

KW - JC virus

KW - Lymphoproliferative diseases

KW - Progressive multifocal leukoencephalopathy

UR - http://www.scopus.com/inward/record.url?scp=0036240013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036240013&partnerID=8YFLogxK

U2 - 10.1002/ajh.10085

DO - 10.1002/ajh.10085

M3 - Article

VL - 70

SP - 51

EP - 54

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -